Alveo Wins XPRIZE Rapid Covid-19 Testing Competition. Click here to read the news.

Diagnosing the Problem

In today’s interconnected world, we are currently facing many global challenges and opportunities surrounding infectious diseases. At Alveo, we are tackling these head-on by creating an agile and dynamic technology platform that is designed to provide rapid, reliable, and economical cloud-based diagnostics for use by Everyone*, Anytime, Everywhere™.

Discovering the Solution

Alveo is poised to create a new ecosystem for the detection of infectious diseases by combining unprecedented nucleic acid detection with molecular biochemistry in a highly efficient design package. Alveo’s cloud-based product platform is designed to enable the creation of vast datasets to help track global infectious disease outbreaks and connect individuals with treatments. Initially, we are developing our platform with tests for Flu A/B, COVID-19, and RSV**.


Alveo aims to overcome the limitations of current diagnostic methods by condensing all of the necessary steps for infectious detection into a single step process. The be.well™ platform that is currently under development is designed to sample preparation, nucleic acid amplification and real-time detection in a single isothermal microfluidic channel. The highlight of this all-inclusive design approach is multiplexing, and the Alveo platform is designed to multiplex 100 or more simultaneous tests from a single sample.

Be Well - Alveo logo
1000 Atlantic Avenue, Suite 114
Alameda, CA 94501 USA

[email protected]

*The be.well system is currently under development to be used by individuals over the age of 18, and for individuals over the age of 18 to perform the test on individuals under 18 years of age.
** The be.well  system is currently under development and has not received clearance, approval, or any other marketing authorization from the U.S. FDA.